<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850028</url>
  </required_header>
  <id_info>
    <org_study_id>201700599</org_study_id>
    <secondary_id>2017-003511-20</secondary_id>
    <secondary_id>NL63047.042.18</secondary_id>
    <nct_id>NCT03850028</nct_id>
  </id_info>
  <brief_title>Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients</brief_title>
  <official_title>Molecular Imaging of Zirconium-89-labeled Atezolizumab as a Tool to Investigate Atezolizumab Biodistribution in High-risk Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular imaging can be used for the noninvasive assessment of biodistribution of monoclonal&#xD;
      antibodies. Atezolizumab has previously successfully been labeled with the radionucleotide&#xD;
      Zirconium-89 (89Zr) and studied in solid malignancies (NCT02453984). The results of&#xD;
      atezolizumab biodistribution can help to get a better understanding of the response&#xD;
      mechanisms, the relation with minimal residual disease, the relation with the status of the&#xD;
      T-cell and natural killer (NK)-cell repertoire and toxicity of programmed death ligand 1&#xD;
      (PDL1) checkpoint inhibition. Possibly in the future this will facilitate optimal patient&#xD;
      selection. Sequential 89Zr-atezolizumab positron emission tomography (PET) scans can provide&#xD;
      information on the dynamics of atezolizumab biodistribution over time. In combination with&#xD;
      repeated characterization of tumor tissue and blood samples, these results can give inside in&#xD;
      primary and acquired resistance.&#xD;
&#xD;
      In this parallel study of the HOVON 151 trial, 89Zr-atezolizumab-PET-scans will be used to&#xD;
      evaluate 20 high risk DLBCL patients before and after induction (R-CHOP) therapy, and at&#xD;
      suspected relapse during or after atezolizumab consolidation (HOVON 151).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a high risk diffuse large B-cell lymphoma (DLBLC) with an international&#xD;
      prognostic score (IPI) &gt; 2, have a high risk of relapse even after achieving a metabolic&#xD;
      complete remission with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab&#xD;
      (R-CHOP) chemo-immunotherapy. Outcome after relapse is dismal. In patients with varies types&#xD;
      of relapsed lymphoma checkpoint inhibition have shown promising results.&#xD;
&#xD;
      In order to improve outcome patients with a high risk DLBCL will be treated in the HOVON 151&#xD;
      trial (EudracT 2017-002605-35) with the monoclonal antibody directed against the immune&#xD;
      checkpoint program death ligand 1 (PDL1) atezolizumab for 1 year after achieving a complete&#xD;
      metabolic remission with R-CHOP.&#xD;
&#xD;
      The observed percentage of PDL1 positive tumor cells in DLBCL cases ranges from 13 to 31%.&#xD;
      For PD-1/PDL1 checkpoint inhibition PDL1 tumor surface expression was proposed as a potential&#xD;
      predictive marker. Despite higher overall response rates in PDL1 positive malignancies&#xD;
      compared to PDL1 negative tumors, responses are seen in PDL1 negative patients nevertheless.&#xD;
      PDL1 status from resected specimens showed a poor correlation to the PDL1 status from matched&#xD;
      biopsies. Furthermore it has been shown that PDL1 expression in tumor biopsies changes with&#xD;
      treatment. Therefore, PDL1 expression assessed by one single biopsy might not be&#xD;
      representative.&#xD;
&#xD;
      Molecular imaging can be used for the noninvasive assessment of biodistribution of monoclonal&#xD;
      antibodies. Atezolizumab has previously successfully been labeled with the radionucleotide&#xD;
      Zirconium-89 (89Zr) and studied in solid malignancies (NCT02453984). The results of&#xD;
      atezolizumab biodistribution can help to get a better understanding of the response&#xD;
      mechanisms, the relation with minimal residual disease, the relation with the status of the&#xD;
      T-cell and natural killer (NK)-cell repertoire and toxicity of programmed death ligand 1&#xD;
      (PDL1) checkpoint inhibition. Possibly in the future this will facilitate optimal patient&#xD;
      selections. Sequential 89Zr-atezolizumab PET scans can provide information on the dynamics of&#xD;
      atezolizumab biodistribution over time. In combination with repeated characterization of&#xD;
      tumor tissue and blood samples, these results can give inside in the primary and acquired&#xD;
      resistance.&#xD;
&#xD;
      In this parallel study of the HOVON 151 trial, 89Zr-atezolizumab-PET-scans will be used to&#xD;
      evaluate 20 high risk DLBCL patients before and after induction (R-CHOP) therapy, and at&#xD;
      suspected relapse during or after atezolizumab consolidation (HOVON 151).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">April 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of 89Zr-atezolizumab</measure>
    <time_frame>From 2 weeks before R-CHOP until 52 weeks after R-CHOP</time_frame>
    <description>The biodistribution of the tracer 89Zr-atezolizumab as assessed with 89Zr-atezolizumab PET scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PDL1 and human leukocyte antigen (HLA) expression using immunohistochemistry (IHC)</measure>
    <time_frame>IHC for PDL1 and HLA expression on archival tumor tissue will be performed after initial biopsy at time of diagnosis.</time_frame>
    <description>Tumor and immune cell PDL1 and HLA expression on archival pre-treatment biopsy via IHC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble programmed death ligand 1 (sPDL1) measurement using an enzyme-linked immunosorbent assay (ELISA).</measure>
    <time_frame>From 2 weeks before R-CHOP until 52 weeks after R-CHOP</time_frame>
    <description>sPDL1 serum levels will be determined with ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiling (GEP) via Nanostring</measure>
    <time_frame>From 2 weeks before R-CHOP until 52 weeks after R-CHOP</time_frame>
    <description>GEP via Nanostring analysis for cell-of origin will be perfomed on archival, paraffin fixed biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Next generation sequencing (NGS) data</measure>
    <time_frame>From 2 weeks before R-CHOP until 52 weeks after R-CHOP</time_frame>
    <description>Mutational analysis will be perfomed on archival, paraffin fixed biopsies.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>T- and NK-cell dynamics in response to R-CHOP therapy</measure>
    <time_frame>From 2 weeks before R-CHOP until 52 weeks after R-CHOP</time_frame>
    <description>Multi-parameter flowcytometry will be used to assess baseline and post induction-therapy status of the T- and NK-cell repertoire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut microbiome dynamics in response to R-CHOP therapy</measure>
    <time_frame>From 2 weeks before R-CHOP until 52 weeks after R-CHOP</time_frame>
    <description>Baseline and post induction-therapy fecal samples will be collected for NGS analysis</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma, Not Otherwise Specified</condition>
  <arm_group>
    <arm_group_label>Imaging cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>89Zr-atezolizumab PET scans</intervention_name>
    <description>The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.&#xD;
These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151).</description>
    <arm_group_label>Imaging cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 (inclusive) years&#xD;
&#xD;
          -  Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma not&#xD;
             otherwise specified (DLBCL-NOS) based upon a representative histology specimen&#xD;
             according to the World Health Organization (WHO) classification, revision 2016 (see&#xD;
             appendix A)&#xD;
&#xD;
          -  Ann Arbor stages II-IV (see appendix B)&#xD;
&#xD;
          -  WHO performance status 0 - 1 (see appendix E)&#xD;
&#xD;
          -  international prognostic index (IPI) ≥ 3 at diagnosis (see appendix C)&#xD;
&#xD;
          -  Negative pregnancy test at study entry&#xD;
&#xD;
          -  Patient is willing and able use adequate contraception during and until 5 months after&#xD;
             the last protocol treatment.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Patient is capable of giving a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Diagnosis&#xD;
&#xD;
          -  All histopathological diagnoses other than DLBCL-NOS according to the WHO&#xD;
             classification, revision 2016 (see appendix A), including:&#xD;
&#xD;
          -  High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations&#xD;
&#xD;
          -  Testicular large B-cell lymphoma&#xD;
&#xD;
          -  Primary mediastinal B cell lymphoma&#xD;
&#xD;
          -  Transformed indolent lymphoma&#xD;
&#xD;
          -  Post-transplant lymphoproliferative disorder&#xD;
&#xD;
        Organ dysfunction&#xD;
&#xD;
          -  Clinical signs of severe pulmonary dysfunction&#xD;
&#xD;
          -  Clinical signs of heart failure (NYHA classification II-IV)&#xD;
&#xD;
          -  Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with&#xD;
             medication.&#xD;
&#xD;
          -  Myocardial infarction during the last 6 months&#xD;
&#xD;
          -  Significant renal dysfunction (serum creatinine ≥ 150 umol/l or clearance ≤ 30ml/min&#xD;
&#xD;
        Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula:&#xD;
&#xD;
        CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females) / (0.815 x serum&#xD;
        creatinine [μmol/L])&#xD;
&#xD;
          -  Inadequate hematological function: hemoglobin &lt; 5.5 mmol/L,absolute neutrophil count&#xD;
             (ANC) &lt; 1.0x10^9/L or platelets &lt; 75x10^9 /L&#xD;
&#xD;
          -  Spontaneous international normalized ratio (INR) &gt; 1.5, activated partial&#xD;
             thromboplastin time (aPTT) &gt;33&#xD;
&#xD;
          -  Significant hepatic dysfunction (total bilirubin ≥ 1.5x upper limit of normal (ULN) or&#xD;
             transaminases ≥ 2.5 x ULN), unless related to Gilberts syndrome.&#xD;
&#xD;
          -  Clinical signs of severe cerebral dysfunction&#xD;
&#xD;
          -  Patients with a history of uncontrolled seizures, central nervous system disorders or&#xD;
             psychiatric disability judged by the investigator to be clinically significant and&#xD;
             adversely affecting compliance to study drugs&#xD;
&#xD;
          -  Major surgery within the last 4 weeks&#xD;
&#xD;
        Known or suspected infection&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or&#xD;
             any major episode of infection requiring treatment with IV antibiotics or&#xD;
             hospitalization within 4 weeks before date of registration. Suspected active or latent&#xD;
             tuberculosis needs to be confirmed by positive interferon gamma (IFN-γ) release assay&#xD;
&#xD;
          -  Patients known to be human immunodeficiency virus (HIV)-positive&#xD;
&#xD;
          -  Active chronic hepatitis B or C infection&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before date of&#xD;
             registration or anticipation that such a live attenuated vaccine will be required&#xD;
             during the study and for a period of 5 months after discontinuation of atezolizumab&#xD;
&#xD;
        Auto-immune&#xD;
&#xD;
          -  Any active or history of documented autoimmune disease, including but not limited to&#xD;
             myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with&#xD;
             antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome,&#xD;
             Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The&#xD;
             following exceptions are allowed: Patients with autoimmune-related hypothyroidism or&#xD;
             type 1 diabetes mellitus who are on stable treatment.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active&#xD;
             pneumonitis per chest CT scan at screening.&#xD;
&#xD;
          -  Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment&#xD;
&#xD;
          -  Regular treatment with corticosteroids within the 4 weeks prior to date of&#xD;
             registration, unless administered for indications other than non-Hodgkin lymphoma&#xD;
             (NHL) at a dose equivalent to &lt; 30 mg/day prednisone/prednisolone.&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Serious underlying medical conditions, which could impair the ability of the patient&#xD;
             to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus,&#xD;
             gastric ulcers, active autoimmune disease)&#xD;
&#xD;
          -  Current participation in another clinical trial interfering with this trial&#xD;
&#xD;
          -  History of active cancer during the past 5 years, except basal cell carcinoma of the&#xD;
             skin or stage 0 cervical carcinoma&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Any psychological, familial, sociological and geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
        Prior treatment&#xD;
&#xD;
          -  Prior treatment with atezolizumab, or anti PD1 or PDL1 antibodies.&#xD;
&#xD;
          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including&#xD;
             anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) therapeutic antibodies.&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including but not limited to&#xD;
             interferon (IFN), interleukin (IL)-2) within 6 weeks or 5 half-lives of the drug,&#xD;
             whichever is shorter, prior to date of registration.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications, including but not limited to&#xD;
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti- tumor&#xD;
             necrosis factor (anti-TNF) agents within 2 weeks prior to date of registration;&#xD;
             inhaled corticosteroids and mineralocorticoids are allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel Nijland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xaver U. Kahle, MD</last_name>
    <phone>+31503612530</phone>
    <email>x.kahle@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcel Nijland, MD</last_name>
    <phone>+31503614582</phone>
    <email>m.nijland@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseé M. Zijlstra, MD, PhD</last_name>
      <phone>+31 (0)20 444 2601</phone>
      <email>j.zijlstra@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne W. Jauw, MD, PhD</last_name>
      <phone>+31 (0)20 444 2604</phone>
      <email>yws.jauw@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Joseé M. Zijlstra, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9100 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xaver U. Kahle, MD</last_name>
      <phone>+31 (0)50 361 2530</phone>
      <email>x.kahle@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marcel Nijland, MD</last_name>
      <phone>+31 (0)50 361 4582</phone>
      <email>m.nijland@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Elisabeth de Vries, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcel Nijland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Marcel Nijland</investigator_full_name>
    <investigator_title>hematologist and priniciple investigator</investigator_title>
  </responsible_party>
  <keyword>high risk DLBCL</keyword>
  <keyword>molecular imaging</keyword>
  <keyword>89Zr-atezolizumab-PET</keyword>
  <keyword>PDL1 imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

